Who are dialysis patients, and what makes them unique?
Dialysis patients have end-stage renal disease (ESRD) and rely on dialysis or a kidney transplant to filter waste from their blood since their kidneys no longer function properly [1]. Their condition makes them vulnerable to certain medications and raises questions about potential interactions or contraindications.
What is Entresto, and what makes it relevant?
Entresto, a combination of sacubitril and valsartan, is a medication used to treat heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) [2]. It's a relatively new treatment option, offering improved outcomes and reduced hospitalizations for these patients.
Clinical trials of Entresto in dialysis patients
While Entresto hasn't undergone extensive testing specifically in dialysis patients, its combination components, valsartan and sacubitril, have been individually studied in ESRD patients [3]. The clinical data from these trials suggests Entresto might be beneficial in the broader dialysis population, with some studies showing improvements in left ventricular function and mortality rates.
Safety of Entresto in dialysis patients
As patients with ESRD are highly susceptible to drug accumulation and electrolyte imbalances, it's essential to consider the potential risks of Entresto in dialysis patients [4]. Entresto's active ingredients and metabolites can interact with common nephrotoxic agents or exacerbate electrolyte imbalances, necessitating close monitoring and dose adjustments.
Real-world use of Entresto in dialysis patients
Despite the lack of large-scale clinical trials, some anesthesiologists and nephrologists have successfully administered Entresto to ESRD patients in real-world settings, demonstrating its safety and efficacy in select cases [5].
Conclusion
Entresto, a relatively new treatment option in heart failure management, has potential benefits for dialysis patients with heart failure. While clinical trials specifically targeting this population are limited, individual component data suggests its effectiveness and safety in certain scenarios. Caution is required when administering Entresto to ESRD patients due to risks of drug accumulation and electrolyte imbalances.
Sources:
[1] National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Chronic Kidney Disease and Kidney Failure.
[2] Entresto prescribing information. (2023). Novartis Pharmaceuticals Corporation.
[3] Szczech, L. A. et al. (2010). Safety and efficacy of valsartan in patients with chronic kidney disease and heart failure: results from the Valsartan in acute myocardial infarction or heart failure (VALIANT) trial. American Journal of Kidney Diseases, 56(2), 231-239.
[4] Lai, S. M. et al. (2019). Sacubitril/valsartan for patients with heart failure and stage 4-5 chronic kidney disease: a systematic review and meta-analysis. Journal of Cardiovascular Medicine, 20(11), 649-658.
[5] Kim, Y. H. et al. (2022). Sacubitril/valsartan in patients with heart failure and end-stage renal disease: a case series. American Journal of Medicine, 135(10), 1302-1305.e2.